Biomarkers in Transplantation—Proteomics and Metabolomics
- 1 April 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 38 (Supplement) , S70-S74
Abstract
Modern multianalyte “omics” technologies allow for the identification of molecular signatures that confer significantly more information than measurement of a single parameter as typically used in current medical diagnostics. Proteomics and metabolomics bioanalytical assays capture a large set of proteins and metabolites in body fluids, cells, or tissues and, complementing genomics, assess the phenome. Proteomics and metabolomics contribute to the development of novel predictive clinical biomarkers in transplantation in 2 ways: they can be used to generate a diagnostic fingerprint or they can be used to discover individual proteins and metabolites of diagnostic potential. Much fewer metabolomics than proteomics biomarker studies in transplant patients have been reported, and, in contrast to proteomics discovery studies, new lead metabolite markers have yet to emerge. Most clinical proteomics studies have been discovery studies. Several of these studies have assessed diagnostic sensitivity and specificity. Nevertheless, none of these newly discovered protein biomarkers have yet been implemented in clinical decision making in transplantation. The currently most advanced markers discovered in proteomics studies in transplant patients are the chemokines CXCL-9 and CXCL-10, which have successfully been validated in larger multicenter trials in kidney transplant patients. These chemokines can be measured using standard immunoassay platforms, which should facilitate clinical implementation. Based on the published evidence, it is reasonable to expect that these chemokine markers can help guiding and individualizing immunosuppressive regimens, may be able to predict acute and chronic T-cell–mediated and antibody-mediated rejection, and may be useful tools for risk stratification of kidney transplant patients.Keywords
This publication has 62 references indexed in Scilit:
- Implementation of proteomic biomarkers: making it workEuropean Journal of Clinical Investigation, 2012
- Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantationLiver Transplantation, 2011
- Urinary Chemokines CXCL9 and CXCL10 Are Noninvasive Markers of Renal Allograft Rejection and BK Viral InfectionAmerican Journal of Transplantation, 2011
- Clinical and Plasma Proteomic Markers Correlating With Chronic Kidney Disease After Liver TransplantationAmerican Journal of Transplantation, 2011
- Profiling the proteome in renal transplantationProteomics – Clinical Applications, 2011
- Chemokines and Their Receptors in Human Renal AllotransplantationTransplantation, 2011
- The role of laboratory medicine in healthcare: quality requirements of immunoassays, standardisation and data management in prospective medicineEPMA Journal, 2010
- Proteomic Signatures in Plasma during Early Acute Renal Allograft RejectionMolecular & Cellular Proteomics, 2010
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006
- Mass spectrometry-based proteomicsNature, 2003